NZB/W Mouse Model

Charles River has characterized a clinically relevant model of lupus, the NZB/W mouse. In this model, lupus develops spontaneously with an increase in autoantibodies at 5 months of age and peak at 8-9 months, which parallels with development of proteinuria, an indicator of kidney dysfunction.


Image of a kidney representing the damage caused by nephritis. Nephritis is an immune complex-mediated autoimmune disease characterized by kidney inflammation. Nephritis is clinically diagnosed through urine tests, blood tests, and kidney biopsies. Charles River has characterized a nephrotoxic nephritis mouse model induced by administration of nephrotoxic antiserum (NTS).

We also offer other kidney models of inflammation, such as our Nephrotoxic Antiserum Mouse Model of Nephritis.
Learn More


Study parameters include in-life clinical evaluation of proteinuria and serum autoantibodies, blood creatinine, and histopathological evaluation of kidney sections together with optional cytokine analysis in serum and kidneys.

Optional Study Endpoints

  • PK/PD blood collections
  • Cytokine/chemokine analysis
  • Clinical chemistry
  • Histopathological evaluation
  • Immunohistochemistry
  • Flow cytometry in lymph nodes or spleen

In-life Readout

  • PROTEINURIA

    charts showing efficacy on proteinuria in the NZB/W model of spontaneous SLE

    Mycophenolate Mofetil (MMF) administered daily at 100 mg/kg shows efficacy on proteinuria in the NZB/W mouse model of spontaneous SLE. 

Ex Vivo Analysis

  • BONE MARROW FLOW CYTOMETRY ANALYSIS

    charts showing shows efficacy via a reduction in the proportion of plasmablasts and plasma cells

    Mycophenolate Mofetil (MMF) administered daily at 100 mg/kg. Compound X caused a decrease in the proportion of bone marrow monocytes.

  • LYMPH NODE FLOW CYTOMETRY ANALYSIS

    charts showing shows efficacy via a reduction in lymph node B cells, monocytes/macrophages, and the activation of monocytes/macrophages

    Mycophenolate Mofetil (MMF) administered daily at 100 mg/kg shows efficacy via a reduction in lymph node B cells, monocytes/macrophages, and the activation of monocytes/macrophages.

  • SPLEEN FLOW CYTOMETRY ANALYSIS

    charts showing efficacy via a reduction in a decrease in spleen B cells, monocytes/macrophages, and the activation of monocytes/macrophages

    Mycophenolate Mofetil (MMF) administered daily at 100 mg/kg shows efficacy via a reduction in spleen B cells, monocytes, and the activation of monocytes (as shown by CD86 expression).